The treatment of the rheumatological manifestations of the inflammatory bowel diseases

Rheumatology International

Volumn 26, Issue 11, 2006, Pages 953-958

  Padovan, Melissa ^a   Castellino, Gabriella ^a   Govoni, Marcello ^a   Trotta, Francesco ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Anti TNF agents; Inflammatory bowel diseases (IBD); Rheumatologic manifestations; Spondyloarthritides; Therapy

Indexed keywords

ANTI TNF ALPHA; AZATHIOPRINE; CYCLOSPORIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ENTERITIS; ENTHESOPATHY; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATIC DISEASE; SPONDYLITIS; SYMPTOMATOLOGY;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; RHEUMATIC DISEASES; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748780684     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-006-0148-x     Document Type: Review

References (44)

1. Orchard TR, Wordsworth BP, Jewell DP (1998) Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut 42:387-391
2. De Keyser F, Elewaut D, De Vos M, De Vlam K, Cuvelier C, Mielants H, Veys EM (1998) Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am 24:785-813
3. Holden W, Orchard T, Wordsworth P (2003) Enteropathic arthritis. Rheum Dis Clin North Am 29:513-530
4. Mielants H, Veys EM, Cuvelier C, de Vos M (1988) Ileocolonscopic findings in seronegative spondyloarthropathies. Br J Rheumatol 27(Suppl 2):95-105
5. Baeten D, De Keyser F, Mielants H, Veys EM (2002) Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 16:537-549
6. Mielants H, Veys EM, Cuvelier C, de Vos M, Goemaere S, De Clercq L, Schotteman L, Elewaut D (1995) The evolution of spondyloarthropathies in relation to gut histology. Part: III relation between gut and joint. J Rheumatol 22:2279-2284
7. Baeten D, De Keyser F, Mielants H, Veys EM (2002) Immune linkages between inflammatory bowel disease and spondyloarthropathies. Curr Opin Rheumatol 14:342-347
8. van Tubergen A, van der Heijde D, Anderson J, Landewé R, Dougados M, Braun J, Bellamy N, Udrea G, van der Linden S (2003) Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis 62:215-221
9. Barkham N, Marzo-Ortega H, McGonagle D, Emery P (2004) How to diagnose axial spondyloarthropathy early. Ann Rheum Dis 63:471-472
10. Smale S, Natt RS, Orchard TR, Russell AS, Bjarnason I (2001) Inflammatory bowel disease and spondyloarthropathy. Arthritis Rheum 44:2728-2736
11. Ward MM (1999) Health-related quality of life in ankylosing spondylitis: survey of 175 patients. Arthritis Care Res 12:247-255
12. van Tubergen A, CoenenJ, Landewé R, Spoorenberg A, Chorus A, Boonen A, van der Linder S, van der Heijde D (2002) Assessment of fatigue in patients with ankylosing spondylitis. A psychometric analysis. Arthrtis Care Res 47:8-16
13. Bjarnason I, Macpherson AJS, Somasundaram S, Teahon K (1993) Non-steroidal anti-inflammatory drugs and Crohn's disease. In: Scholmeric J, Kruis W, Goebbell H, Hoenberger W, Gross V (eds) Inflammatory bowel diseases: pathophysiology as basis of treatment. Kluwer, Lancaster, pp 208-222
14. Bjarnason I, Hayllar J, Macpherson AJ, Russell AS (1993) Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. Gastroenterology 104:1832-1847
15. Rampton DS, Sladen GE (1981) Relapse of ulcerative proctocolitis during treatment with NSAIDs. Postgrad Med J 57:297-299
16. Riley SA, Mani V, Goodman MJ, Lucas S (1990) Why do patients with ulcerative colitis relapse? Gut 31:179-183
17. Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, Pallone F (2004) Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment Pharmacol Ther 19:755-764
18. Van Tubergen A, Landewé R, van der Heijde D, Hidding A, Wolter N, Asscher M, Falkenbach A, Genth E, The HG, van der Linden S (2001) Combined Spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Care Res 45:430-438
19. Dougados M, van der Linden S, Lerislao-Repo M, Hutfeldt B, Juhlin R, Veys E, Zeidler H, Kuien TK, Olivieri I, Dijkmans B et al (1995) Sulfasalazine in the treatment of spondyloarthropathy. A randomised, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 38:618-627
20. Clegg DO, Reda DJ, Weisman MH, Cush JJ, Vasey FB, Schumacher HR Jr, Budiman-Mak E, Balestra DJ, Blackburn WD, Cannon GW, Inman RD, Alepa FP, Mejias E, Cohen MR, Makkena R, Mahowald ML, Higashida J, Silverman SL, Parhami N, Buxbaum J, Haakenson CM, Ward RH, Manaster BJ, Anderson RJ, Henderson WG et al (1996) Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 39:2004-2012
21. Taggart AG, Gardiner P, McEvoy FM, Hopkins R, Bird H (1996) Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomised controlled study. Arthritis Rheum 39:1400-1405
22. Thomson GT, McKibbon C, Inman RD (1994) Mesalamine therapy in Reiter's syndrome. J Rheumatol 21:570-572
23. De Keyser F, Van Damme N, De Vos M, Mielants H, Veys EM (2000) Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res 49:47-54
24. Chen J, LC (2004) Methotrexate for ankylosing-spondylitis. Cochrane Database Syst Rev (3):CD004524
25. Gonzales-Lopez L, Garcia-Gonzalez A, Vasquez-Del Mercado M, Munoz-Valle JF, Gamez-Nava JI (2004) Efficacy of methotrexate in ankylosing spondylitis. J Rheumatol 31:1568-1574
26. Haibel H, Rudwaleit M, Braun J, Sieper J (2005) Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 64:124-126
27. Biasi D, Carletto A, Caramaschi P, Pacor ML Maleknia T, Bambara LM (2000) Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol 19:114-117
28. De Keyser F, Van Damme N, De Vos M, Mielants H, Veys EM (2000) Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm Res 49:47-54
29. Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, Skeith KJ, Aaron SL, Homik J, Davis P, Sholter D, Russell AS (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46:766-773
30. Huang F, Gu J, Zhao W, Zhu J, Zhang J, Yu DT (2002) One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 47:249-254
31. Bollow M, Fisher T, Reisshauer H, Backhaus M, Sieper J, Hamm B, Braun J (2000) Quantitative analyse of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis as detected by magnetic resonance imaging in spondyloarthropathies. Ann Rheum Dis 59:135-140
32. McCormack G, Moriarty D, O'Donoghue DP, McCormick PA, Sheahan K, Baird AW (2001) Tissue cytokine and chemokine expression in inflammatory boweldisease. Inflamm Res 50:491-495
33. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, Sorensen H, Zeidler H, Thriene W, Sieper J (2002) Treatment of active ankylosing spondylitis with infliximab: a double blind placebo controlled multicenter trial. Lancet 359:1187-1193
34. Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. New Engl J Med 346:1349-1356
35. Davis JC, van der Hejide D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W (2003) Recombinant human tumor necrosis factor receptor (Etanercept) for treating ankylosing spondylitis. Arthritis Rheum 48:3230-3236
36. Braun J, Brandt J, Listing J, Zink A, Alten R, Baumester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sorensen H, Zeidler H, Reddig J, Sieper J (2003) Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Arthritis Rheum 48:2224-2233
37. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola EM, Salvarani C, Sanmarti R, Sany J, Sibilia J, Sieper J, van der Linden S, Veys E, Appel AM, Fatenejad S (2004) Outcomes of multicenter randomizes clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594-1600
38. Van der Heijde D, Dijkmans BA, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2004) Efficacy and safety of infliximab in patients with ankylosing spondylitis: result of a 23-week randomized, placebo controlled trial (ASSERT). Ann Rheum Dis 52:82-591
39. van den Bosch F, Kruithof E, De Vos M, De Keyser F, Mielants H (2000) Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 356:1821-1822
40. Ellman MH, Hanauer S, Sitrin M, Cohen R (2001) Crohn's disease arthritis treated with infliximab: an open trial in four patients. J Clin Rheumatol 7:67-71
41. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P (2003) Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 62:74-76
42. Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O (2004) The effect of infliximab on extraintestinal manifestations of Crohn's disease. Rheumatol Int 12:63-66
43. Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci-Cerinic M (2004) Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy in inducing and maintaining remission of musculoskeletal and gut manifestations. Ann Rheum Dis 63:1664-1669
44. Jarnerot G, Hertervig, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B (2005) Infliximab as rescue therapy in severe to moderate ulcerative colitis: a randomised, placebo-controlled study. Gastroenterology 128:1805-1811